These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25261094)

  • 1. Biomodulatory therapy induces complete molecular remission in chemorefractory acute myeloid leukemia.
    Thomas S; Schelker R; Klobuch S; Zaiss S; Troppmann M; Rehli M; Haferlach T; Herr W; Reichle A
    Haematologica; 2015 Jan; 100(1):e4-6. PubMed ID: 25261094
    [No Abstract]   [Full Text] [Related]  

  • 2. Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia.
    Gruber E; Franich RL; Shortt J; Johnstone RW; Kats LM
    Leukemia; 2020 Dec; 34(12):3388-3392. PubMed ID: 32655143
    [No Abstract]   [Full Text] [Related]  

  • 3. A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy.
    Wass M; Göllner S; Besenbeck B; Schlenk RF; Mundmann P; Göthert JR; Noppeney R; Schliemann C; Mikesch JH; Lenz G; Dugas M; Wermke M; Röllig C; Bornhäuser M; Serve H; Platzbecker U; Foerster KI; Burhenne J; Haefeli WE; Müller LP; Binder M; Pabst C; Müller-Tidow C;
    Leukemia; 2021 Mar; 35(3):701-711. PubMed ID: 32561840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy.
    Ivanoff S; Gruson B; Chantepie SP; Lemasle E; Merlusca L; Harrivel V; Charbonnier A; Votte P; Royer B; Marolleau JP
    Am J Hematol; 2013 Jul; 88(7):601-5. PubMed ID: 23619977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study.
    Lou Y; Shao L; Mao L; Lu Y; Ma Y; Fan C; Jiang H; Li J; Jin J
    Leuk Res; 2020 Apr; 91():106317. PubMed ID: 32092584
    [No Abstract]   [Full Text] [Related]  

  • 6. Azacitidine as the post-remission therapy for elderly patients with acute myeloid leukemia.
    Yamamoto R; Yokoyama A; Yoneda M; Ohashi K; Hosoda T; Kagoo T; Boku S; Ueno H; Yano T
    Ann Hematol; 2014 Dec; 93(12):2081-2. PubMed ID: 24863693
    [No Abstract]   [Full Text] [Related]  

  • 7. Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.
    Ramos F; Thépot S; Pleyer L; Maurillo L; Itzykson R; Bargay J; Stauder R; Venditti A; Seegers V; Martínez-Robles V; Burgstaller S; Récher C; Debén G; Gaidano G; Gardin C; Musto P; Greil R; Sánchez-Guijo F; Fenaux P;
    Leuk Res; 2015 Mar; 39(3):296-306. PubMed ID: 25601157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predonor lymphocyte infusion treatment with 5-azacytidine as salvage treatment in relapsed acute myeloid leukaemia secondary to myelodysplastic syndrome.
    Villela L; Anders V; Bolaños-Meade J
    Anticancer Drugs; 2010 Apr; 21(4):469. PubMed ID: 20216343
    [No Abstract]   [Full Text] [Related]  

  • 9. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission.
    Boumber Y; Kantarjian H; Jorgensen J; Wen S; Faderl S; Castoro R; Autry J; Garcia-Manero G; Borthakur G; Jabbour E; Estrov Z; Cortes J; Issa JP; Ravandi F
    Leukemia; 2012 Nov; 26(11):2428-31. PubMed ID: 22665218
    [No Abstract]   [Full Text] [Related]  

  • 10. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
    Ram R; Amit O; Zuckerman T; Gurion R; Raanani P; Bar-On Y; Avivi I; Wolach O
    Ann Hematol; 2019 Aug; 98(8):1927-1932. PubMed ID: 31187237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transfusion independence and survival in patients with acute myeloid leukemia treated with 5-azacytidine.
    Gavillet M; Noetzli J; Blum S; Duchosal MA; Spertini O; Lambert JF
    Haematologica; 2012 Dec; 97(12):1929-31. PubMed ID: 22875616
    [No Abstract]   [Full Text] [Related]  

  • 12. Managing post allograft relapse of myeloid neoplasms: azacitidine and donor lymphocyte infusions as salvage therapy.
    Claiborne J; Bandyopathyay D; Roberts C; Hawks K; Aziz M; Simmons G; Wiedl C; Chung H; Clark W; McCarty J; Toor A
    Leuk Lymphoma; 2019 Nov; 60(11):2733-2743. PubMed ID: 31046498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The euphoria of hypomethylating agents in MDS and AML: is it justified?
    Sekeres MA
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of priming with granulocyte macrophage colony-stimulating factor plus all-trans retinoic acid combined with remission induction chemotherapy in patients with acute myeloid leukemia.
    Shin HJ; Chung JS; Choi YJ; Cho GJ
    Am J Clin Oncol; 2009 Jun; 32(3):227-32. PubMed ID: 19433969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.
    Craddock C; Labopin M; Robin M; Finke J; Chevallier P; Yakoub-Agha I; Bourhis JH; Sengelov H; Blaise D; Luft T; Hallek M; Kröger N; Nagler A; Mohty M
    Haematologica; 2016 Jul; 101(7):879-83. PubMed ID: 27081178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
    Mattison R; Jumonville A; Flynn PJ; Moreno-Aspitia A; Erlichman C; LaPlant B; Juckett MB
    Leuk Lymphoma; 2015 Jul; 56(7):2061-6. PubMed ID: 25329007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
    Fenaux P; Mufti GJ; Hellström-Lindberg E; Santini V; Gattermann N; Germing U; Sanz G; List AF; Gore S; Seymour JF; Dombret H; Backstrom J; Zimmerman L; McKenzie D; Beach CL; Silverman LR
    J Clin Oncol; 2010 Feb; 28(4):562-9. PubMed ID: 20026804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis.
    Stevens B; Winters A; Gutman JA; Fullerton A; Hemenway G; Schatz D; Miltgen N; Wei Q; Abbasi T; Vali S; Singh NK; Drusbosky L; Cogle CR; Hammes A; Abbott D; Jordan CT; Smith C; Pollyea DA
    Leuk Res; 2019 Jun; 81():43-49. PubMed ID: 31009835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of therapy-related myeloid neoplasms treated with azacitidine.
    Fianchi L; Criscuolo M; Lunghi M; Gaidano G; Breccia M; Levis A; Finelli C; Santini V; Musto P; Oliva EN; Leoni P; Aloe Spiriti A; D'Alò F; Hohaus S; Pagano L; Leone G; Voso MT
    J Hematol Oncol; 2012 Aug; 5():44. PubMed ID: 22853048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
    Wei AH; Döhner H; Pocock C; Montesinos P; Afanasyev B; Dombret H; Ravandi F; Sayar H; Jang JH; Porkka K; Selleslag D; Sandhu I; Turgut M; Giai V; Ofran Y; Kizil Çakar M; Botelho de Sousa A; Rybka J; Frairia C; Borin L; Beltrami G; Čermák J; Ossenkoppele GJ; La Torre I; Skikne B; Kumar K; Dong Q; Beach CL; Roboz GJ;
    N Engl J Med; 2020 Dec; 383(26):2526-2537. PubMed ID: 33369355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.